Literature DB >> 8445464

A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers.

R O Greer1, J E Lindenmuth, T Juarez, A Khandwala.   

Abstract

A double-blind trial of amlexanox (C16H14N2O4) was carried out in 32 patients with recurrent oral aphthous ulcerations. During the treatment period, which lasted for 3 days, patients received either placebo topical paste or 5% amlexanox paste. The paste was applied by the investigator twice per day for 3 days and once on the fourth day. Efficacy was assessed by the following parameters: 1) pain measured by the patients marking a 15-cm line between poles connoting no pain versus severe pain; 2) erythema evaluated by the investigator on a four-point scale ranging from none to strong; 3) size determined by investigator measurement of the perpendicular dimensions of the ulcer; and 4) an investigator's improvement scale consisting of six rank-ordered points from -1 for worsening of the ulcer with respect to previously described criteria to +4 when the ulcer had healed completely. All evaluations were based on a comparison with the day 1 visit of the patient. Outcomes for patients receiving the active ingredient were superior on all four criteria of effectiveness. Group differences for all criteria but pain reduction were statistically significant (P < .05). No side effects were reported. It was concluded that amlexanox is effective in reducing aphthous ulcer erythema, pain, and lesional size.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445464     DOI: 10.1016/s0278-2391(10)80164-8

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  14 in total

1.  Clinical study to know the efficacy of Amlexanox 5% with other topical Antiseptic, Analgesic and Anesthetic agents in treating minor RAS.

Authors:  D D Darshan; C N Vijay Kumar; A D Manoj Kumar; N S Manikantan; Dhanya Balakrishnan; M P Uthkal
Journal:  J Int Oral Health       Date:  2014-02-26

Review 2.  The treatment of chronic recurrent oral aphthous ulcers.

Authors:  Andreas Altenburg; Nadine El-Haj; Christiana Micheli; Marion Puttkammer; Mohammed Badawy Abdel-Naser; Christos C Zouboulis
Journal:  Dtsch Arztebl Int       Date:  2014-10-03       Impact factor: 5.594

3.  Oral medicine: amlexanox.

Authors:  Vasudev Ballal; Jothi V
Journal:  Br Dent J       Date:  2014-09       Impact factor: 1.626

Review 4.  Effect of laser on pain relief and wound healing of recurrent aphthous stomatitis: a systematic review.

Authors:  Valerie G A Suter; Sophia Sjölund; Michael M Bornstein
Journal:  Lasers Med Sci       Date:  2017-03-27       Impact factor: 3.161

Review 5.  Mucocutaneous lesions of Behcet's disease.

Authors:  Erkan Alpsoy; Christos Constantin Zouboulis; George Edward Ehrlich
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

6.  Update in the management of extraintestinal manifestations of inflammatory bowel disease.

Authors:  Seema A Patil; Raymond K Cross
Journal:  Curr Gastroenterol Rep       Date:  2013-03

7.  New Evidence-Based Treatment Approach in Behçet's Disease.

Authors:  Erkan Alpsoy
Journal:  Patholog Res Int       Date:  2011-10-05

8.  Effectiveness of Amlexanox and Adcortyl for the treatment of recurrent aphthous ulcers.

Authors:  Farid Abbasi; Maryam Raoof; Roya Khatami; Niloofar Shadman; Farnaz Borjian-Boroojeni; Farahnaz Nazari
Journal:  J Clin Exp Dent       Date:  2016-10-01

9.  A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial.

Authors:  Wenxia Meng; Yi Dong; Jie Liu; Zhi Wang; Xiaobo Zhong; Ruiyang Chen; Hongmei Zhou; Mei Lin; Lu Jiang; Feng Gao; Tao Xu; Qianming Chen; Xin Zeng
Journal:  Trials       Date:  2009-05-06       Impact factor: 2.279

10.  Short-Term Efficacy of Pudilan Keyanning Toothpaste in Treatment of Minor Recurrent Aphthous Ulcers.

Authors:  Yingming Yang; Tao Zhang; Zibo Dong; Yang Wu; Xiao Hong; Tao Hu
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.